EI
MRSN

Ellevest Inc’s Mersana Therapeutics MRSN Stock Holding History

Ellevest Inc’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2
Closed -$234 – 1139
2023
Q1 		$234 Hold
2
– – ﹤0.01% 1753
2022
Q4 		$334 Hold
2
– – ﹤0.01% 1670
2022
Q3 		$0 Hold
2
– – ﹤0.01% 1764
2022
Q2 		$0 Buy
+2
New +$188 ﹤0.01% 1571
2021
Q4 		– Hold
0
– – – 1562
2021
Q3 		– Hold
0
– – – 1510

Other funds holding MRSN

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Ellevest Inc's MRSN Position: Q2 2023 in Review

Ellevest Inc sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 2 shares — an estimated $234 sold.

Ellevest Inc first reported a position in MRSN in Q2 2022 and held it in 4 quarters. The position peaked at $334 in Q4 2022. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • Ellevest Inc reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ellevest Inc sold 2 Mersana Therapeutics shares in Q2 2023, an estimated $234.
  • Ellevest Inc first reported a position in Mersana Therapeutics in Q2 2022 and held it in 4 quarters.
  • Ellevest Inc's Mersana Therapeutics position peaked at $334 in Q4 2022.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.